Lake Charles Clinical Trials (LCCT) is the only research clinic specializing in psychiatric clinical trials in Southwest Louisiana (servicing a catchment area of over 200,000). Privileges at a full-service hospital-- located within the same building complex-- include access to a 46-bed inpatient psychiatric unit accommodating child, adult and geriatric patients.
Phase II - IV clinical trials for adults and adolescents in the following diagnoses:
- Bipolar disorder
- Schizophrenia
- Major depression
- Anxiety disorders
- ADHD
LCCT has worked with the following pharmaceutical companies (trials sponsors): AstraZeneca, Bristol-Myers Squibb, Janssen, Ortho-McNeil, Eli Lilly, Shire-Richwood, GlaxoSmithKline, Memory, Pfizer, Organon, Solvay, Vanda, and Wyeth. LCCT has on numerous occasions also worked with Clinical Research Organizations (CROs), including: INC Research, Ingenix, Lineberry/Constella Group, Ockham, Paragon, Parexel, PharmaNet, and Quintiles.
LCCT has conducted over twenty-five industry-sponsored trials' eight of which took place in the past year; there are ten ongoing trials at various stages of enrollment (with six more to begin in 2007).
Kashianth G. Yadalam, DFAPA - Principal Investigator (PI) Twenty-three years of combined experience and certified as a Physician Investigator by the Academy of Pharmaceutical Physicians and Investigators. Dr. Yadalam has conducted NIH-funded research and has published over 30 articles and abstracts.
Charles A. Murphy, III, MD - Sub-Investigator. Child psychiatrist for over 15 years with three years of clinical trial experience.
Charles B. Woodard, MD, FACC - Sub-InvestigatorCardiologist with almost 30 years of experience who provides medical management for all of the study participants.
Currently at LCCT, there are five full-time research coordinators as well as a records maintenance and data-monitoring support staff of seven individuals (including a phlebotomist/EKG technician, a regulatory affairs specialist, and a part-time recruiter). The coordinators have been certified by Rater Qualifying specialists in the use of diagnostic instruments and rating scales relating to the above diagnoses.
LCCT provides inpatient and outpatient treatment for child, adolescent, adult and geriatric patients
Psychiatry/Psychology
LCCT has secure drug and data storage facilities, clinical laboratory, pharmacy, and computer-related equipment (we can capture and transmit data electronically via a T1 Internet connection), centrifuge, freezer (-20° C), refrigerator (2-8° C), EKG machine, and dry ice access.
Kashinath G. Yadalam, MD, DFAPA - Certified Physician Investigator
Medical Director/ CEO
Lake Charles Clinical Trials
2770 3rd Avenue, Suite 340
Lake Charles, LA 70601
USA
337-494-3266
337-494-2089 (fax)
yadalamk@msn.com
- Assess long term safety, tolerability and effectiveness of lurasidone over a 12 month double blind period followed by a 6 month open label extension phase
- Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
- Efficacy and safety study of adjunctive AZD6765 in subjects with severe Major Depressive Disorder and a history of poor response to antidepressants
- Gastrointestional randomization event and safety open label NSAID study
- Randomized 6 week, double blind, placebo controlled, fixed flexible dose, parallel group study of lurasidone adjunctive to lithium or divalproex for treatment of Bipolar I depression
- Randomized 6 week, double blind, placebo controlled, fixed flexible dose, parallel group study of lurasidone for treatment of Bipolar I depression
- Randomized, Double blind, placebo controlled, parallel group, efficacy and safety trial of bapineuzumab in patients with mild to moderate Alzheimer's disease
- Study to assess the efficacy and safety of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder
- Study to assess the efficacy and safety of olanzapine and fluoxetine combination versus placebo in patients ages 10 to 17 in the treatment of major depressive disorder associated with Bipolar I disorder
- Study to evaluate the efficacy tolerability, and safety of an intramuscular depot formulation of apripirazole as maintenance therapy in patients with schizophrenia
- To evaluate the efficacy and safety of Armodanifil as adjunctive therapy in adults with schizophrenia
- To evaluate the safety, efficiacy, and tolerability of cariprazine relative to placebo in patients with acute exacerbation of schizophrenia